Lupin launches generic equivalent of Vivlodex Capsules
The product is indicated for management of osteoarthritis (OA) pain.
Mumbai, Baltimore: Drugmaker, Lupin Limited, has recently announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration(USFDA). Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg, and 10 mg, of Zyla Life Sciences US, Inc.The product is indicated for management of...
Mumbai, Baltimore: Drugmaker, Lupin Limited, has recently announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration(USFDA).
Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg, and 10 mg, of Zyla Life Sciences US, Inc.
The product is indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately USD 11 million in the U.S. (IQVIA MAT October 2020).
Read also: Lupin gets USFDA nod for generic equivalent of Jublia Topical Solution
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd